Literature DB >> 15189344

Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity.

Sandra M Cardoso1, Isabel Santana, Russell H Swerdlow, Catarina R Oliveira.   

Abstract

Alzheimer's disease (AD) brain reveals high rates of oxygen consumption and oxidative stress, altered antioxidant defences, increased oxidized polyunsaturated fatty acids, and elevated transition metal ions. Mitochondrial dysfunction in AD is perhaps relevant to these observations, as such may contribute to neurodegenerative cell death through the formation of reactive oxygen species (ROS) and the release of molecules that initiate programmed cell death pathways. In this study, we analyzed the effects of beta-amyloid peptide (Abeta) on human teratocarcinoma (NT2) cells expressing endogenous mitochondrial DNA (mtDNA), mtDNA from AD subjects (AD cybrids), and mtDNA from age-matched control subjects (control cybrids). In addition to finding reduced cytochrome oxidase activity, elevated ROS, and reduced ATP levels in the AD cybrids, when these cell lines were exposed to Abeta 1-40 we observed excessive mitochondrial membrane potential depolarization, increased cytoplasmic cytochrome c, and elevated caspase-3 activity. When exposed to Abeta, events associated with programmed cell death are activated in AD NT2 cybrids to a greater extent than they are in control cybrids or the native NT2 cell line, suggesting a role for mtDNA-derived mitochondrial dysfunction in AD degeneration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189344     DOI: 10.1111/j.1471-4159.2004.02438.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  94 in total

1.  Maternal family history is associated with Alzheimer's disease biomarkers.

Authors:  Robyn A Honea; Eric D Vidoni; Russell H Swerdlow; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

3.  Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice.

Authors:  Latha Devi; Masuo Ohno
Journal:  Neurobiol Dis       Date:  2011-09-13       Impact factor: 5.996

Review 4.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

Review 5.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease.

Authors:  Heather M Wilkins; Russell H Swerdlow
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 7.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

9.  RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction.

Authors:  Kazuhiro Takuma; Fang Fang; Wensheng Zhang; Shiqiang Yan; Emiko Fukuzaki; Heng Du; Alexander Sosunov; Guy McKhann; Yoko Funatsu; Noritaka Nakamichi; Taku Nagai; Hiroyuki Mizoguchi; Daisuke Ibi; Osamu Hori; Satoshi Ogawa; David M Stern; Kiyofumi Yamada; Shirley Shidu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

10.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.